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Background: The ankle-brachial blood pressure index (ABI) is an independent predictor of mortality in hemodialysis
patients. In the present study, we investigated the factors that predict changes in the ABI in hemodialysis patients.
Methods: A total of 61 consecutive patients receiving maintenance hemodialysis who successfully underwent ABI
examinations in 2005 and 2011 were enrolled in this study. The change in the ABI (2011 measurement versus 2005
measurement) was estimated. We set the baseline at 2011 and investigated the patient outcomes. Furthermore, we
compared the change in the ABI and several clinical factors observed in 2005.
Results: The mean follow-up period was 3.1 ± 0.7 years. In the univariate Cox proportional hazard analysis,
predictive variables for mortality included ABI (0.43 [0.25–0.64]; [per 0.1 increase]) and the change in the ABI
(0.62 [0.49–0.79]; [per 0.1 increase]). Patient age was negatively correlated and the serum creatinine level was
positively correlated with the change in the ABI (P = 0.030 and 0.022, respectively).
Conclusions: We confirmed that not only the value of the ABI itself but also the change in the ABI was a
risk factor for mortality among hemodialysis patients. The change in the ABI was negatively correlated with
age and was positively correlated with the serum creatinine level. Careful observation of the ABI is needed
for old patients and patients with a low serum creatinine level.
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Epidemiological and clinical studies of the general popula-
tion have demonstrated that the presence of peripheral ar-
tery disease (PAD) is associated with an increased risk of
myocardial infarction and stroke [1, 2]. PAD is a regular
complication of hemodialysis patients [3, 4] and is
associated with poor outcomes [4–9]. Clinically, the ankle-
brachial blood pressure index (ABI) is highly correlated
with PAD of the lower extremities [10], and ABI is an inde-
pendent predictor of all-cause mortality in hemodialysis
patients [6–9]. A recent study also revealed that not only
the value of the ABI itself but also the rate of the reduction* Correspondence: sotsubo@hb.tp1.jp
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[11]. In the present study, we investigated the effect of
changes in the ABI on mortality and the factors that pre-
dict changes in the ABI in hemodialysis patients.Methods
A total of 61 consecutive patients receiving maintenance
hemodialysis who successfully underwent ABI examina-
tions in both 2005 and 2011 were retrospectively en-
rolled in this study. All patients were not treated by
interventional or surgical repair for PAD during 2005
and 2011. Clinical data including age, sex, durations of
hemodialysis therapy, presence of diabetes mellitus and/
or hypertension complications, and biological examina-
tions were collected from the patient’s records. Hyper-
tension was defined as a systolic blood pressure of
140 mmHg or higher, a diastolic blood pressure ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Background characteristics of the study participants
All patients (n = 61)
Age (year) 57.2 ± 13.2
Gender (M/F) 33/28
Duration of HD (year) 19.8 (11.1–28.1)
Albumin (g/dL) 3.7 ± 0.3
Creatinine (mg/dL) 11.8 ± 2.3
Uric acid (mg/dL) 7.7 ± 1.4
Corrected calcium (mg/dL) 9.4 ± 0.8
Phosphate (mg/dL) 5.4 ± 1.4
Ca × P (mg/dL)2 50.6 ± 12.2
Total cholesterol (mg/dL) 159 ± 36
Triglyceride (mg/dL) 102 ± 41
C-reactive protein (mg/dL) 0.07 (0.05–0.16)
Hemoglobin (g/dL) 10.7 ± 0.8
Primary Cause of ESKD, n (%)
Chronic glomerulonephritis 43 (70.5)
Diabetic nephropathy 5 (8.2)
Polycystic kidney disease 3 (4.9)
Chronic pyelonephritis 1 (1.7)
Post transplantation 8 (13.1)
Unknown and others 1 (1.7)
Complication, n (%)
Hypertension 36 (59.0)
Diabetes mellitus 9 (14.8)
Mean ± SD, median (interquartile range: IQR)
HD hemodialysis, Ca calcium, P phosphate, ESKD end-stage kidney disease
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tensive drugs. Diabetes mellitus was defined as fasting glu-
cose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, or the
use of medication. A peripheral blood sample was ob-
tained before hemodialysis on a Monday or a Tuesday.
The ABI was determined in all the patients using an ABI
form (Colin, Japan), which simultaneously measures bilat-
eral arm and ankle blood pressures (brachial and posterior
tibial arteries, respectively) using an oscillometric method.
The blood pressure was measured after the patients
had rested in a supine position for at least 5 min.
The ABI was calculated using the ratio of the ankle
systolic pressure divided by the arm systolic pressure.
Blood pressure measurement in the arm with blood
access is not desirable. So, the systolic pressure of the
arm without dialysis access was used for the calcula-
tion. Patients who failed to measure ABI of either
side of the legs were excluded from the study. The
change in the ABI (2011 measurement versus 2005
measurement) was estimated. Delta ABI was defined
and estimated as the following formula.
DeltaABI ¼ ABI in2011−ABI in2005
We set the baseline at 2011 and investigated the
patient outcomes. The clinical endpoints were defined as
cardiovascular disease (CVD) events and death from any
cause. CVD events include cardiac events (angina pectoris,
hospitalization for heart failure, percutaneous coronary
intervention, coronary artery bypass surgery, or acute
myocardial infarction), cerebral events (hospitalization for
cerebral infarction or bleeding), aortic dissection
(hospitalization for aortic dissection), and PAD events
(hospitalization for PAD including intervention, graft by-
pass surgery, or amputation). The smaller values for either
ABI or delta ABI among the two values of both legs were
adopted and incorporated into the analysis. Averages of
ABI and delta ABI values for both legs were also
examined.
Furthermore, we compared the change in the ABI (in-
cluding both legs) and several clinical factors observed
in 2005. Oral informed consent was obtained from the
subjects. This study was conducted in accordance with
the principles of the Declaration of Helsinki and permit-
ted by the research ethics committee of the Tokyo
Women’s Medical University (Approved No. 3601).
The data were expressed as means ± SD or median
(interquartile range, IQR). A univariate Cox proportional
hazard model was used to examine the predictors of the
overall outcomes. A simple regression analysis was used
to examine the relationship between two continuous var-
iables. All the statistical calculations were performed
using JMP 5.1 software. P values less than 0.05 were
considered statistically significant.Results
The mean follow-up period was 3.1 ± 0.7 years. The
patient background characteristics are shown in Table 1.
The mean age was 57.2 ± 13.2 years, and the mean dur-
ation of hemodialysis therapy was 19.3 ± 8.7 years. The
results of the biochemistry analyses and the primary
causes of end-stage kidney disease are also shown in
Table 1. Chronic glomerulonephritis was the major
cause of end-stage kidney disease in this study. Hyper-
tension and diabetes mellitus were observed in 59.0 and
14.8 % of the study participants, respectively.
During the follow-up period, seven deaths were re-
corded. The causes of death were infection in five cases,
cerebrovascular disease in one case, and unknown in
one case. Table 2 shows the Cox proportional hazard
analysis of the covariates for predicting mortality. In the
univariate analysis, predictive variables for mortality
included old age (HR, 1.06 [1.00–1.13]; P = 0.048 [per
1 year increase]), low level of serum albumin (HR, 0.12
[0.02–0.82]; P = 0.032 [per 1 g/dL increase]), creatinine
(HR, 0.49 [0.32–0.71]; P < 0.001 [per 1 mg/dL increase]),
uric acid (HR, 0.42 [0.20–0.80]; P = 0.008 [per 1 mg/dL
Table 2 Cox proportional hazard analysis of the covariates for
predicting mortality (univariate analysis)
Parameters (n = 61) Hazard ratio (95 % CI) P value
Age (per 1 year) 1.06 (1.00 to 1.13) 0.048
Gender (M) 0.77 (0.34 to 1.64) 0.493
Duration of HD (per 1 year) 1.00 (0.91 to 1.09) 0.969
Albumin (per 1 g/dL) 0.12 (0.02 to 0.82) 0.032
Creatinine (per 1 mg/dL) 0.49 (0.32 to 0.71) <0.001
Uric acid (per 1 mg/dL) 0.42 (0.20 to 0.80) 0.008
Corrected calcium (per 1 mg/dL) 1.14 (0.42 to 2.81) 0.789
Phosphate (per 1 mg/dL) 0.26 (0.09 to 0.65) 0.002
Ca × P (per 1 (mg/dL)2) 0.98 (0.92 to 1.03) 0.446
Total cholesterol (per 1 mg/dL) 1.00 (0.98 to 1.02) 0.919
Triglyceride (per 1 mg/dL) 1.00 (0.98 to 1.02) 0.916
C-reactive protein (per 1 mg/dL) 1.04 (0.29 to 1.75) 0.912
Hemoglobin (per 1 g/dL) 0.60 (0.25 to 1.44) 0.250
Hypertension (Y) 2.15 (0.89 to 9.36) 0.095
Diabetes mellitus (Y) 0.95 (0.22 to 2.29) 0.918
ABI (per 0.1)a 0.43 (0.25 to 0.64) <0.0001
ΔABI (per 0.1)a 0.62 (0.49 to 0.79) <0.001
ΔABI = ABI in 2011 − ABI in 2005
HD hemodialysis, Ca calcium, P phosphate, ABI ankle-brachial blood
pressure index
aABI and ΔABI: smaller values among both legs
Table 3 Cox proportional hazard analysis of the covariates for
predicting composite endpoints including cardiovascular events
and mortality (univariate analysis)
Parameters (n = 61) Hazard ratio (95 % CI) P value
Age (per 1 year) 1.04 (1.00 to 1.09) 0.044
Gender (M) 1.25 (0.73 to 2.25) 0.419
Duration of HD (per 1 year) 1.03 (0.97 to 1.09) 0.357
Albumin (per 1 g/dL) 0.16 (0.05 to 0.64) 0.011
Creatinine (per 1 mg/dL) 0.67 (0.52 to 0.86) 0.001
Uric acid (per 1 mg/dL) 0.80 (0.51 to 1.21) 0.294
Corrected calcium (per 1 mg/dL) 1.68 (0.74 to 3.64) 0.211
Phosphate (per 1 mg/dL) 0.60 (0.34 to 0.96) 0.033
Ca × P (per 1 (mg/dL)2) 0.96 (0.91 to 1.01) 0.084
Total cholesterol (per 1 mg/dL) 0.99 (0.97 to 1.00) 0.141
Triglyceride (per 1 mg/dL) 1.01 (1.00 to 1.02) 0.153
C-reactive protein (per 1 mg/dL) 1.44 (0.84 to 2.05) 0.154
Hemoglobin (per 1 g/dL) 0.52 (0.27 to 0.98) 0.042
Hypertension (Y) 1.40 (0.81 to 2.67) 0.239
Diabetes mellitus (Y) 0.62 (0.15 to 1.40) 0.299
ABI (per 0.1)a 0.65 (0.50 to 0.86) 0.025
ΔABI (per 0.1)a 0.73 (0.61 to 0.90) 0.005
ΔABI = ABI in 2011 − ABI in 2005
HD hemodialysis, Ca calcium, P phosphate, ABI ankle-brachial blood
pressure index
a ABI and ΔABI: smaller values among both legs
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[per 1 mg/dL increase]), ABI (smaller values among both
legs) (HR, 0.43 [0.25–0.64]; P < 0.0001 [per 0.1 in-
crease]), and delta ABI (smaller values among both legs)
(HR, 0.62 [0.49–0.79]; P < 0.001 [per 0.1 increase]). The
average values of ABI and delta ABI among both legs
were also risk factors for mortality (HR, 0.47 [0.29–
0.71]; P < 0.001 [per 0.1 increase], HR, 0.49 [0.31–0.74];
P < 0.001 [per 0.1 increase], respectively).
Table 3 shows the Cox proportional hazard analysis of
the covariates for predicting composite endpoints in-
cluding CVD events and mortality. Nine CVD events
were observed during the follow-up period including
three in cardiac events (two angina pectoris, one acute
myocardial infarction), three in cerebral events (one
cerebral infarction, one acute subdural hematoma, one
chronic subdural hematoma), two in PAD events (inter-
ventional therapy for PAD), and one in aortic dissection.
In the univariate analysis, predictive variables for the
composite endpoints included old age (HR, 1.04 [1.00–
1.09]; P = 0.044 [per 1 year increase]), low level of serum
albumin (HR, 0.16 [0.05–0.64]; P = 0.011 [per 1 g/dL in-
crease]), creatinine (HR, 0.67 [0.52–0.86]; P = 0.001 [per
1 mg/dL increase]), and phosphate (HR, 0.60 [0.34–
0.96]; P = 0.033 [per 1 mg/dL increase]), low level of
hemoglobin (HR, 0.52 [0.27–0.98]; P = 0.042 [per 1 g/dL
increase]), ABI (smaller values among both legs) (HR,0.65 [0.50–0.86]; P = 0.025, [per 0.1 increase]), and delta
ABI (smaller values among both legs) (HR, 0.73 [0.61–
0.90]; P = 0.005, [per 0.1 increase]). The average values
of ABI and delta ABI among both legs were also risk fac-
tors for composite endpoints including CVD events and
mortality (HR, 0.68 [0.50–0.92]; P = 0.014 [per 0.1 in-
crease], HR, 0.01 [0.00–0.33]; P = 0.001 [per 0.1 increase],
respectively).
Table 4 shows the relationships between the change in
the ABI (2005 to 2011) and other clinical parameters ob-
served in 2005. Patient age was negatively correlated and
the serum creatinine level was positively correlated with
the change in the ABI (P = 0.030 and 0.022, respectively).
Discussion
We confirmed that not only the value of the ABI itself
but also the change in the ABI was a risk factor for mor-
tality among hemodialysis patients. The change in the
ABI was negatively correlated with patient age and was
positively correlated with the serum creatinine level.
PAD is a regular complication of hemodialysis pa-
tients, and the HEMO study reported a prevalence of
23.0 % [12]. In addition, we previously reported a high
prevalence (22.1 %) of PAD among hemodialysis patients
[7]. PAD is recognized as a polyvascular disease because
of the frequent coexistence of coronary artery and
Table 4 The relationship between the change of ABI (2005 to
2011) and other clinical parameters of 2005
r P value
Age (year) -0.1968 0.030
Duration of HD (year) 0.0762 0.404
Albumin (g/dL) 0.0490 0.592
Creatinine (mg/dL) 0.2079 0.022
Corrected calcium (mg/dL) 0.0783 0.391
Phosphate (mg/dL) −0.0371 0.685
Ca × P (mg/dL)2 0.0542 0.553
Total cholesterol (mg/dL) −0.1385 0.128
Triglyceride (mg/dL) −0.0002 0.998
C-reactive protein (mg/dL) 0.1233 0.176
Hemoglobin (g/dL) −0.0134 0.884
fABI ankle-brachial blood pressure index, HD hemodialysis, Ca calcium,
P phosphate
Abe et al. Renal Replacement Therapy  (2016) 2:40 Page 4 of 5cerebrovascular atherosclerosis [13]. Moreover, we re-
cently showed that, in a study examining 117
hemodialysis patients, infection was significantly more
prevalent in the PAD group than in the non-PAD group
[8]. Both the short-term and long-term outcomes of
hemodialysis patients with PAD have been reported to
be poor [6–9]. The ABI is a simple, reliable diagnostic
tool that can be used to define the existence and severity
of PAD. We also confirmed that a low ABI was a risk
factor for mortality.
Recently, Kuwahara et al. estimated 300 hemodialysis
patients and showed that a higher rate of ABI decline
was a prominent predictor of survival among patients
receiving hemodialysis therapy (HR, 4.044; P < 0.001 [per
0.1/year decrease]) in multivariate Cox analysis [11]. We
also showed that the change in the ABI was a risk factor
for mortality, but it was a univariate analysis because of
the small sample size. Their observation period for the
change in the ABI was 1 year, which was 6 years in our
study. We conformed that the change in the ABI in a
relatively long period was also a risk factor for mortality.
We added analysis of CVD events and conformed that
not only the low level of the ABI itself but also the re-
duction of the ABI were both significant risk factors for
CVD events and mortality.
Another recent study reported that a high fasting glu-
cose level and old age were independent determinants of
the accelerated progression of the ABI [14]. We also ob-
served a negative correlation between age and the
change in the ABI. We could not examine the fasting
glucose level. However, we did observe that the serum
creatinine level was positively correlated with the change
in the ABI. We previously compared PAD patients and
non-PAD patients and found that the serum albumin
and creatinine levels were lower, the serum C-reactiveprotein level was higher, and the hemoglobin level was
lower among PAD hemodialysis patients than non-PAD
patients [8]. A low serum creatinine level is not only
correlated with a low ABI but also predicts further
reductions in the ABI. Serum creatinine is a marker of
nutrition [15], and malnutrition and atherosclerosis are
well known to affect each other in a condition known as
malnutrition inflammation atherosclerosis (MIA) syn-
drome [16]. A malnutrition status is correlated with a
low serum creatinine level and causes atherosclerosis,
which reduces the ABI. The reason why other markers
of malnutrition, such as the serum albumin level, did
not predict the change in the ABI remained unclear. A
relatively long-term observation period may be one of
the reasons.
Our study had several limitations. The study was a
retrospective examination of patients evaluated at a sin-
gle institution, and differences in care, including medica-
tions, occurred over the course of the study. The
prevalence of diabetes mellitus and nephrosclerosis was
relatively low because of our institution’s specialty. But
we first revealed that low serum level of creatinine pre-
dict reduction of ABI.
Conclusions
We confirmed that not only the value of the ABI itself
but also the change in the ABI was a risk factor for mor-
tality among hemodialysis patients. Careful attention
should be given to changes in the ABI as well as the
value of the ABI itself. The change in the ABI was nega-
tively correlated with age and was positively correlated
with the serum creatinine level. Careful observation of
the ABI is needed for old patients and patients with a
low serum creatinine level.
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